Dicerna Pharmaceuticals Inc Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016
Total revenue
Revenue
Operating expenses:
Research and development
General and administrative
Litigation expense
Total operating expenses
Loss from operations
Other income (expense):
Interest income
Interest expense
Other (expense) income
Total other income, net
Net loss
Dividends on redeemable convertible preferred stock
Deemed dividend related to beneficial conversion feature of redeemable convertible preferred stock
Deemed dividend on conversion of redeemable convertible preferred stock (Note 8)
Deemed dividend on conversion of redeemable convertible preferred stock
Net loss attributable to common stockholders
Net loss per share — basic and diluted (in dollars per share)
Weighted average common shares outstanding — basic and diluted (in shares)

Comments